Pictet Alternative Advisors has launched a strategy aimed at investing in best-in-class biotech and healthcare-focused venture capital, growth, and private equity funds globally and will dedicate a substantial allocation to co-investments within its covered segments of high conviction.

The strategy aims to take advantage of strong macro drivers as governments, businesses and individuals prioritise the improvement of health across society.

Yann Mauron

The funds will look to target high conviction investments in five key segments (therapeutics, diagnostics, digital health, medical technology, and health care and services providers) to create a diversified portfolio of private health care companies.

Yann Mauron (pictured), investment manager for the strategy said: “Health is a major priority for society as a whole. We are at an inflection point for medical breakthroughs: investment is growing, regulation is becoming more supportive, and technology is able to offer more potential solutions.”

Pierre Stadler, head of thematic private equity, added: “From a private equity standpoint, the five areas provide opportunities across the full spectrum of company maturities. Deal flow in therapeutics, digital health and diagnostics is particularly strong in early and growth stages. Medtech and care providers, meanwhile, tend to be more attractive at buyout stage.”